Skip to main content

abelacimab

abelacimab: 4 clinical trials tracked.

abelacimab evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about abelacimab, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (4)

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT07739888Registry updated 2026-07-31·Phase 3
Not yet recruiting

Primary endpoint: Time to first ISTH major Bleeding events

Interventionalopen2,500 targetStarted 2027-12Completion 2030-12Novartis Pharmaceuticals

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

NCT05712200Registry updated 2026-07-13·Phase 3
Recruiting

Primary endpoint: Efficacy: Time to first event of ischemic stroke or systemic embolism (SE)

InterventionalRandomizeddouble2,500 targetStarted 2022-12Completion 2027-1250 sites · United StatesAnthos Therapeutics, Inc.

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

NCT05171075Registry updated 2026-04-17·Phase 3
Terminated

Primary endpoint: Time to first event of centrally adjudicated VTE recurrence

InterventionalRandomizedsingle417 targetStarted 2022-09Completion 2026-0450 sites · Australia, Austria, Canada, China…Anthos Therapeutics, Inc.

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

NCT05171049Registry updated 2026-02-23·Phase 3
Terminated

Primary endpoint: Time to first event of centrally adjudicated VTE recurrence

InterventionalRandomizedsingle1,150 targetStarted 2022-05Completion 2026-0250 sites · Australia, Austria, Canada, China…Anthos Therapeutics, Inc.